NCT01954693View on ClinicalTrials.gov

A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis

PHASE2UnknownINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

August 6, 2018

Study Completion Date

August 6, 2018

Conditions

Tuberous Sclerosis

Interventions

DRUG

Placebo

5mg daily administered for 6 months as two oral 2.5 mg tablets once daily.

DRUG

Everolimus (RAD001)

5mg daily administered for 6 months as two oral 2.5 mg tablets once daily

Trial Locations (1)

CF14 4YS

Cardiff University, Cardiff

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Novartis

INDUSTRY

lead

Cardiff University

OTHER